Effects of Estrogen Plus Progestin on Risk of Fracture and Bone Mineral Density: The Women's Health Initiative Randomized Trial

JAMA

Volumn 290, Issue 13, 2003, Pages 1729-1738

  Cauley, Jane A ^a,b   Robbins, John ^c   Chen, Zhao ^d   Cummings, Steven R ^e   Jackson, Rebecca D ^f   LaCroix, Andrea Z ^g   LeBoff, Meryl ^h   Lewis, Cora E ⁱ   McGowan, Joan ^j   Neuner, Joan ^k   Pettinger, Mary ^g   Stefanick, Marcia L ^l   Wactawski Wende, Jean ^m   Watts, Nelson B ⁿ  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

^e CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^f THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^g Fred Hutchinson Cancer Research Center   (United States)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

ⁱ University of Alabama at Birmingham   (United States)

^j NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^k MEDICAL COLLEGE OF WISCONSIN   (United States)

^l STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m UNIVERSITY AT BUFFALO   (United States)

ⁿ UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTROGEN; GESTAGEN; CONJUGATED ESTROGEN; MEDROXYPROGESTERONE ACETATE; PROGESTERONE DERIVATIVE;

ADULT; AGED; ANAMNESIS; ARTICLE; BODY MASS; BONE DENSITY; BONE MINERAL; CALCIUM INTAKE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ESTROGEN ACTIVITY; FALLING; FAMILY HISTORY; FEMALE; FOLLOW UP; FRACTURE; HIGH RISK PATIENT; HIP; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SCORING SYSTEM; SMOKING; TABLET; DOUBLE BLIND PROCEDURE; ESTROGEN THERAPY; MIDDLE AGED; MULTICENTER STUDY; OSTEOPOROSIS; PROPORTIONAL HAZARDS MODEL; RISK;

AGED; BONE DENSITY; DOUBLE-BLIND METHOD; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; FRACTURES, BONE; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; OSTEOPOROSIS; POSTMENOPAUSE; PROGESTERONE CONGENERS; PROPORTIONAL HAZARDS MODELS; RISK;

EID: 0141705375     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.290.13.1729     Document Type: Article

References (36)

1. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
2. Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials. 1998;19:61-109.
3. Kristal AR, Shattuck AL, Williams AE. Food frequency questionnaires for diet intervention research. In: Proceedings of the 17th National Nutrient Databank Conference, June 7-10, 1992; Baltimore, Md. Washington, DC: International Life Sciences Institute Press; 1994:110-125.
4. Ensrud KE, Palermo L, Black DM, et al. Hip and calcaneal bone loss increase with advancing age: longitudinal results from the study of osteoporotic fractures. J Bone Miner Res. 1995;10:1778-1787.
5. Expert Panel on the Identification, Evaluation, and Treatment of Overweight in Adults. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary. Am J Clin Nutr. 1998;68:899-917.
6. Black DM, Steinbuch M, Palermo L, et al. An assessment tool for predicting fracture risk in postmenopausal women. Osteoporos Int. 2001;12:519-528.
7. Kanis JA, Melton LJ III, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9:1137-1141.
8. Handa VL, Landerman R, Hanlon JT, Harris T, Cohen HJ. Do older women use estrogen replacement? data from the Duke Established Populations for Epidemiologic Studies of the Elderly (EPESE). J Am Geriatr Soc. 1996;44:1-6.
9. Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR. Estrogen replacement therapy and fractures in older women. Ann Intern Med. 1995;122: 9-16.
10. Weiss NS, Ure CL, Ballard JH, Williams AR, Daling JR. Decreased risk of fractures of hip and lower forearm with postmenopausal use of estrogen. N Engl J Med. 1980;303:1195-1198.
11. Wells G, Tugwell P, Shea B, et al. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev. 2002;23:529-539.
12. Torgerson DL, Bell-Syer SE. Hormone replacement therapy and prevention of nonvertebral fractures. JAMA. 2001;285:2891-2897.
13. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy. JAMA. 2002;288:872-881.
14. Grady D, Cummings SR. Postmenopausal hormone therapy for prevention of fractures: how good is the evidence? JAMA. 2001;285:2909-2011.
15. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. JAMA. 2003;289:2651-2662.
16. Melton LJ III, Crowson CS, O'Fallon WM. Fracture incidence in Olmsted County, Minnesota: comparison of urban with rural rates and changes in urban rates overtime. Osteoporos Int. 1999;9:29-37
17. Black DM, Cummings SR, Karpf DB, et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996;348:1535-1541.
18. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA. 1999;282: 1344-1352.
19. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med. 2001;344:333-340.
20. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998; 280:2077-2082.
21. Cauley JA, Petrini AM, LaPorte RE, et al. The decline of grip strength in the menopause: relationship to physical activity, estrogen use and anthropometric factors. J Chronic Dis. 1987;40:115-120.
22. Brown BW, Birge SJ, Kohrt WM. Hormone replacement therapy does not augment gains in muscle strength or fat-free mass in response to weightbearing exercise. J Gerontol A Biol Sci Med Sci. 1997; 52:B166-B170.
23. Seeley DG, Cauley JA, Grady D, Browner WS, Nevitt MC, Cummings SR. Is postmenopausal estrogen therapy associated with neuromuscular function or falling in elderly women? Arch Intern Med. 1995;155:293-299.
24. Hulley SB, Grady D, Bush TL, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605-613.
25. Cauley JA, Black DM, Barrett-Connor E, et al. The effects of hormone replacement therapy on clinical fractures and height loss: the Heart and Estrogen/Progestin Replacement Study (HERS). Am J Med. 2001; 110:442-450.
26. Hulley SB, Furberg C, Barrett-Connor E, et al. Non-cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study follow-up (HERS II). JAMA. 2002; 288:58-66.
27. Jamal S, Browner WS, Bauer DC, Cummings SR. Intermittent use of nitrates increases BMD: the Study of Osteoporotic Fractures. J Bone Miner Res. 1998; 13:1755-1759.
28. Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H. HMG-CoA reductase inhibitors and the risk of fractures. JAMA. 2000;283:3205-3210.
29. Nelson HD, Helfano M, Wolf SH, Allan JD. Screening for postmenopausal osteoporosis: a review of the evidence from the US Preventive Services Task Force. Ann Intern Med. 2002;137:529-541.
30. Black DM, Arden NK, Palermo L, Pearson J, Cummings SR. Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. J Bone Miner Res. 1999;14:821-828.
31. Cooper C, O'Neill T, Silman AJ. The epidemiology of vertebral fractures. Bone. 1993;14:S89-S97.
32. Jacobsen SJ, Goldberg J, Miles TP, Brody J, Stiers W, Rimm AA. Race and sex differences in mortality following fracture of the hip. Am J Public Health. 1992; 82:1147-1150.
33. Hannan EL, Magaziner J, Wang JJ, et al. Mortality and locomotion 6 months after hospitalization for hip fracture: risk factors and risk adjusted hospital outcomes. JAMA. 2001;285:2736-2742.
34. Kado DM, Palermo WS, Nevitt MC, Genant HK, Cummings SR. Vertebral fractures and mortality in older women: a prospective study. Arch Intern Med. 1999; 159:1215-1220.
35. Nevitt MC, Ettinger B, Black DM, et al. The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med. 1998;128:793-800.
36. Hays J, Ockene JK, Brunner RL, et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med. 2003;348:1839-1854.